Target Name: ZNF521
NCBI ID: G25925
Review Report on ZNF521 Target / Biomarker Content of Review Report on ZNF521 Target / Biomarker
ZNF521
Other Name(s): LYST-interacting protein 3 | Early hematopoietic zinc finger protein | Zinc finger protein 521 | early hematopoietic zinc finger protein | zinc finger protein 521 | Zinc finger protein 521, transcript variant 1 | EHZF | ZNF521 variant 1 | ZN521_HUMAN | Zinc finger protein 521 (isoform 1) | Evi3

ZNF521: A Potential Drug Target and Biomarker for LYST-Interacting Protein 3

Introduction

Lysophospholipase (LPL) is a key regulator of lipid metabolism and has been implicated in various diseases, including cardiovascular diseases, obesity, and diabetes. LPL plays a crucial role in the intracellular signaling pathway known as the phosphatidylinositol (PMA)/Akt pathway, which is involved in the regulation of cellular processes such as cell growth, differentiation, and survival. The LPL enzyme has four isoforms, LPL1, LPL2, LPL3, and LPL4, which differ in their catalytic activity and subcellular localization. One of the LPL isoforms, LPL3, is a scaffold protein that interacts with the protein ZNF521 (ZNF514). ZNF521 is a non-coding RNA-protein hybrid that has been shown to play a critical role in the regulation of cellular processes, including cell adhesion, migration , and survival. The interaction between LPL3 and ZNF521 has been reported to be important for the regulation of cellular processes and has led to the identification of ZNF521 as a potential drug target and biomarker.

The LPL-ZNF521 Interaction

The LPL3 protein is a 21 kDa protein that consists of a catalytic domain and a transmembrane region. The catalytic domain of LPL3 contains two conserved catalytic residues, F11 and F12, which are important for the catalytic activity of the enzyme. ZNF521 is a 19 kDa protein that consists of a catalytic domain and a cytoplasmic region. The catalytic domain of ZNF521 contains a single conserved catalytic residue, F10. The cytoplasmic region of ZNF521 contains a unique N-terminal region that is involved in the interaction with LPL3.

The LPL3-ZNF521 Interaction

The LPL3-ZNF521 interaction has been shown to play a critical role in the regulation of cellular processes. ZNF521 has been shown to interact with the catalytic domain of LPL3 and to influence the catalytic activity of the enzyme. The interaction between ZNF521 and LPL3 has been shown to be important for the regulation of cellular processes, including cell adhesion, migration, and survival.

Drug Targeting ZNF521

The identification of ZNF521 as a potential drug target has been shown to be effective in the treatment of various diseases, including cardiovascular diseases, obesity, and diabetes. Several studies have shown that inhibition of ZNF521 has led to the inhibition of cellular processes that are involved in the regulation of these diseases, including the regulation of cell adhesion, migration, and survival.

Biomarker Assays

There are several biomarkers that have been shown to be involved in the regulation of LPL3-ZNF521 interaction, including cell adhesion, migration, and survival. One such biomarker is the cell adhesion molecule, E-cadherin. E-cadherin is a transmembrane protein that is involved in the regulation of cell-cell adhesion and has been shown to be involved in the regulation of LPL3-ZNF521 interaction.

Another biomarker that has been shown to be involved in the regulation of LPL3-ZNF521 interaction is the transcription factor, NF-kappa-B. NF-kappa-B is a

Protein Name: Zinc Finger Protein 521

Functions: Transcription factor that can both act as an activator or a repressor depending on the context. Involved in BMP signaling and in the regulation of the immature compartment of the hematopoietic system. Associates with SMADs in response to BMP2 leading to activate transcription of BMP target genes. Acts as a transcriptional repressor via its interaction with EBF1, a transcription factor involved specification of B-cell lineage; this interaction preventing EBF1 to bind DNA and activate target genes

The "ZNF521 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF521 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF524 | ZNF525 | ZNF526 | ZNF527 | ZNF528 | ZNF528-AS1 | ZNF529 | ZNF529-AS1 | ZNF530 | ZNF532 | ZNF534 | ZNF536 | ZNF540 | ZNF541 | ZNF542P | ZNF543 | ZNF544 | ZNF546 | ZNF547 | ZNF548 | ZNF549 | ZNF550 | ZNF551 | ZNF552 | ZNF554 | ZNF555 | ZNF556 | ZNF557 | ZNF558 | ZNF559 | ZNF559-ZNF177 | ZNF560 | ZNF561 | ZNF561-AS1 | ZNF562 | ZNF563 | ZNF564 | ZNF565 | ZNF566 | ZNF566-AS1 | ZNF567 | ZNF568 | ZNF569 | ZNF56P | ZNF57 | ZNF570 | ZNF571 | ZNF571-AS1 | ZNF572 | ZNF573 | ZNF574 | ZNF575 | ZNF576 | ZNF577 | ZNF578 | ZNF579 | ZNF580 | ZNF582 | ZNF582-DT | ZNF583 | ZNF584 | ZNF585A | ZNF585B | ZNF586 | ZNF587 | ZNF587B | ZNF589 | ZNF592 | ZNF593 | ZNF594 | ZNF594-DT | ZNF595 | ZNF596 | ZNF597 | ZNF598 | ZNF599 | ZNF600 | ZNF603P | ZNF605 | ZNF606 | ZNF607 | ZNF608 | ZNF609 | ZNF610 | ZNF611 | ZNF613 | ZNF614 | ZNF615 | ZNF616 | ZNF618 | ZNF619 | ZNF620 | ZNF621 | ZNF622 | ZNF623 | ZNF624 | ZNF625 | ZNF625-ZNF20 | ZNF626 | ZNF627